Cite
Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects.
MLA
Busnelli, Marco, et al. “Fenretinide Treatment Accelerates Atherosclerosis Development in ApoE-Deficient Mice in Spite of Beneficial Metabolic Effects.” British Journal of Pharmacology, vol. 177, no. 2, Jan. 2020, pp. 328–45. EBSCOhost, https://doi.org/10.1111/bph.14869.
APA
Busnelli, M., Manzini, S., Bonacina, F., Soldati, S., Barbieri, S. S., Amadio, P., Sandrini, L., Arnaboldi, F., Donetti, E., Laaksonen, R., Paltrinieri, S., Scanziani, E., & Chiesa, G. (2020). Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects. British Journal of Pharmacology, 177(2), 328–345. https://doi.org/10.1111/bph.14869
Chicago
Busnelli, Marco, Stefano Manzini, Fabrizia Bonacina, Sabina Soldati, Silvia Stella Barbieri, Patrizia Amadio, Leonardo Sandrini, et al. 2020. “Fenretinide Treatment Accelerates Atherosclerosis Development in ApoE-Deficient Mice in Spite of Beneficial Metabolic Effects.” British Journal of Pharmacology 177 (2): 328–45. doi:10.1111/bph.14869.